PAB Australian patent granted for targeted cancer drugs • A patent covering the use of Patrys’ novel Deoxymab platform for the targeted delivery of anticancer drugs using nanoparticles has been granted in Australia • This first patent covers the use of Deoxymabs (both PAT-DX1 and PAT-DX3) conjugated to nanoparticles (NPs) for both the diagnosis and treatment of multiple types of cancer • Patents covering other applications for Deoxymab/PAT-DX1 have already been granted in key markets such as the US, Europe, China and Japan Melbourne, Australia; 6 October 2020: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, is pleased to announce the Australian patent (patent number: 2017286733) titled “Antibody-mediated Autocatalytic, Targeted Delivery of Nanocarrier to Tumors” has been granted. This patent covers Patrys’ novel Deoxymab 3E10 nanoparticle technology (for example PAT-DX1-NP) and includes specific claims covering the use of several different types of nanoparticle carriers conjugated to Deoxymabs for both the diagnosis and treatment of multiple types of cancers.
